NCT02323126 - Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 9, 2015

Primary Completion Date

September 23, 2019

Study Completion Date

February 5, 2021

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

EGF816

EGF816 150 mg once daily (QD) administered orally as a capsule

DRUG

INC280

INC280 400 mg twice daily (BID) administered orally as a tablet

DRUG

Nivolumab

Nivolumab 3 mg/kg every 2 weeks (Q2W) administered by intravenous infusion

Trial Locations (13)

Novartis Investigative Site, Camperdown

Novartis Investigative Site, Chermside

Novartis Investigative Site, Chur

Novartis Investigative Site, Madrid

Novartis Investigative Site, Málaga

Novartis Investigative Site, Aviano

Novartis Investigative Site, La Tronche

Novartis Investigative Site, Cologne

University of Texas MD Anderson Cancer Center Thoractic Head/Neck Med.Onc(2), Houston

Novartis Investigative Site, Singapore

Novartis Investigative Site, Perugia

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Alicante